

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Brian R. MURPHY et al.

Application No.: 09/733,692

Confirmation No.: 3239

Filed: December 8, 2000

Art Unit: 1648

For: USE OF RECOMBINANT PARAINFLUENZA
VIRUSES (PIVs) AS VECTORS TO PROTECT
AGAINST INFECTION AND DISEASE
CAUSED BY PIV AND OTHER HUMAN
PATHOGENS

Examiner: S. B. Chen

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FINAL REJECTION)

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. **LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

☒ Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.

III. CONCISE EXPLANATION OF THE RELEVANCE

(Check at least one box)

☒ a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

☒ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: An English language Abstract is provided for literature reference Mayr et al., Zbl. Bakt. Hyg., pp. 375-390 (1978).

☒ c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

☒ d. OTHER - The following additional information is provided for the Examiner's consideration. Applicant was unable to obtain copies of the references identified in the attached SB08 form as IU, IV, IW and IX. Reference IU is cited in the specification as filed on page 11, lines 24-25. Reference IV is cited in the specification as filed on page 7, lines 18-20, lines 22-24, and line 32 through to line 3 on page 8, and page 10, lines 11-14. Reference IW is cited on page 83 at lines 4-5. Reference IX is cited on page 9 at lines 7-10. References BE (WO 98/53078) and BH (WO 01/04320) were cited in the International Preliminary Examination Report in the corresponding PCT application

THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(d): After the mailing date of a Final Action under § 1.113. See the Statement Under 37 C.F.R. § 1.97(e).

IV. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check only one box)

The undersigned hereby states that:

☐ a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

☐ b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

☐ d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

V. PAYMENT OF FEES (check one box)


☒ The required fee is listed on the attached Fee Transmittal.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: September 1, 2006

Respectfully submitted,

By 
Mark J. Nuell
Registration No.: 36,623
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s):

- ☒ PTO-SB08
- ☒ Documents
- ☒ Foreign Search Report – PCT/US98/10551;
- ☐ Fee
- ☒ Other: IPER – PCT/US98/10551; IPER-PCT/US00/33293

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/733,692	
			Filing Date	December 8, 2000	
			First Named Inventor	Brian R. Murphy	
			Art Unit	1618	
			Examiner Name	Stacy Brown Chen	
Sheet	1	of	6	Attorney Docket Number	1173-1050PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	U.S. 6,264,957	07-24-2001	Collins et al.	
	AB	U.S. 5,993,824	11-30-1999	Murphy et al.	
	AC	U.S. 6,689,367	02-10-2004	Collins et al.	
	AD	U.S. 6,410,023	06-25-2002	Durbin et al.	
	AE	U.S. 6,699,476	03-21-2004	Collins et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ -Kind Code ⁵ (if known)			
	BA	WO	98/02530	01-22-1998	Murphy et al.	
	BB	WO	97/06270	02-20-1997	Schweiz et al.	
	BC	WO/00	06/1737	10-19-2000	Murphy et al.	
	BD	WO	98/53078	01-26-1998	Murphy et al.	
	BE	WO	01/04320	01-18-2001	Schmidt et al.	
	BF	EP	702 085	03-20-1996	Conzelmann	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Anderson et al., <i>J. Infect. Dis.</i> 151:626-633, 1985		
	CB	Bailly et al., <i>J. Virol.</i> 74:3188-3195, 2000		
	CC	Bailly et al., <i>Virus Genes</i> 20:173-82, 2000		
	CD	Baron et al., <i>J. Virol.</i> 71:1265-1271, 1997		
	CE	Beeler et al., <i>J. Virol.</i> 63:2941-2950, 1989		
	CF	Bellanti, <i>Pediatrics</i> 48:715-29, 1971		
	CG	Belshe et al., <i>Infect. Immun.</i> 37:160-5, 1982		
	CH	Belshe & Hissom, <i>J. Med. Virol.</i> 10:235-42, 1982		
	CI	Belshe et al., <i>N. Engl. J. Med.</i> 338:1405-1412, 1998		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/733,692	
			Filing Date	December 8, 2000	
			First Named Inventor	Brian R. Murphy	
			Art Unit	1618	
			Examiner Name	Stacy Brown Chen	
Sheet	2	of	6	Attorney Docket Number	1173-1050PUS1

	CJ	Black & Sheridan, <i>N. Engl. J. Med.</i> 263:165-169, 1960	
	CK	Blanchard et al., <i>J. Gen. Virol.</i> 79:1159-1167, 1998	
	CL	Bousse et al., <i>Virology</i> 204:506-14, 1994	
	CM	Bray & Lai, <i>Proc. Natl. Acad. Sci. USA</i> 88:10342-6, 1991	
	CN	Bucholz et al. <i>J. Virol.</i> 73:251-259, 1999	
	CO	Bukreyev et al., <i>J. Virol.</i> 70:6634-41, 1996	
	CP	Bukreyev et al., <i>Proc. Natl. Acad. Sci. USA</i> 96:2367-72, 1999	
	CQ	Buser, <i>N. Engl. J. Med.</i> 277:250-1, 1967	
	CR	Calain & Ruox, <i>J. Virol.</i> 67:4822-30, 1993	
	CS	Carroll & Moss, <i>Virology</i> 238:198-211, 1997	
	CT	Chen et al., <i>J. Infect. Dis.</i> 162:1036-42, 1990	
	CU	Cheng et al., <i>Proc. Natl. Acad. Sci. USA</i> 91:5695-5699, 1994	
	CV	Clements et al., <i>J. Clin. Microbiol.</i> 29:1175-82, 1991	
	CW	Coates et al., <i>Am. J. Epidemiol.</i> 83:299-313, 1966	
	CX	Coelingh et al., <i>Virology</i> 162:137-143, 1988	
	CY	Collins et al., 3rd ed. In " <i>Fields Virology</i> ," B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus, Eds., Vol. 1, pp. 1205-1243. Lippincott-Raven Publishers, Philadelphia, 1996	
	CZ	Collins et al., <i>Proc. Natl. Acad. Sci. USA</i> 92:11563-11567, 1995	
	DA	Conzelmann, <i>J. Gen. Virol.</i> 77:381-89, 1996	
	DB	Corsaro and Pearson, <i>Somatic Cell Genetics</i> 7:603-616, 1981	
	DC	Crookshanks & Belshe, <i>J. Med. Virol.</i> 13:243-9, 1984	
	DD	Crowe, <i>Vaccine</i> 13:415-421, 1995	
	DE	Cutts et al., <i>Biologicals</i> 25:323-38, 1997	
	DF	Deng et al., <i>Arch. Virol. Suppl.</i> 13:115-30, 1997	
	DG	Deng et al., <i>Virology</i> 209:457-69, 1995	
	DH	Deng, et al., <i>Virology</i> 253:43-54, 1999	
	DI	Dimock & Collins, <i>J. Virol.</i> 67: 2772-8, 1993	
	DJ	Drexler et al., <i>J. Gen. Virol.</i> 79:347-352, 1998	
	DK	Drillien et al., <i>Proc. Natl. Acad. Sci. USA</i> 85:1252-6, 1988	
	DL	Durbin et al., <i>J. Infect. Dis.</i> 179:1345-51, 1999	
	DM	Durbin et al., <i>Vaccine</i> 16:1324-30, 1998	
	DN	Durbin et al., <i>Virology</i> 235:323-332, 1997	
	DO	Durbin et al., <i>Virology</i> 261:319-30, 1999	
	DP	Durbin et al., <i>Virology</i> 234:74-83, 1997	
	DQ	Durbin et al., <i>J. Virol.</i> 74:6821-31, 2000	
	DR	Elango et al., <i>J. Virol.</i> 57:481-489, 1986	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/733,692	
			Filing Date	December 8, 2000	
			First Named Inventor	Brian R. Murphy	
			Art Unit	1618	
			Examiner Name	Stacy Brown Chen	
Sheet	3	of	6	Attorney Docket Number	1173-1050PUS1

	DS	Fenner et al., <i>Scand. J. Immunol.</i> 24:341-349, 1986	
	DT	Fernie et al., <i>Proc. Soc. Exp. Biol. Med.</i> 171:266-271, 1982	
	DU	Finke & Cozelmann, <i>J. Virol.</i> 71:7281-8, 1997	
	DV	Fooks et al., <i>J. Gen. Virol.</i> 79:1027-31, 1998	
	DW	Fulginiti et al., <i>JAMA</i> 202:1075-80, 1967	
	DX	Galinski et al., <i>Virology</i> 165: 499-510, 1988	
	DY	Galinski M. S. In Kingsbury, D. W. (Ed.), <i>The Paramyxoviruses</i> , pp. 537-568, Plenum Press, New York, 1991	
	DZ	Galletti et al., <i>Vaccine</i> 13:197-201, 1995	
	EA	Garcin et al., <i>EMBO J.</i> 14:6087-6094, 1995	
	EB	Gellin & Katz, <i>J. Infect. Dis.</i> 170:S3-14, 1994	
	EC	Graham and Van der Eb, <i>Virology</i> 52:456-467, 1973	
	ED	Grosfeld et al., <i>J. Virol.</i> 69:5677-5686, 1995	
	EE	Guirakhoo et al., <i>Virology</i> 257:363-72, 1999	
	EF	Haas et al., <i>Current Biol.</i> 6:315-324, 1996	
	EG	Hall et al., <i>Virus Res.</i> 22:173-184, 1992	
	EH	Halsey et al., <i>N. Engl. J. Med.</i> 313:544-9, 1985	
	EI	Hasan et al., <i>J. Gen. Virol.</i> 78:2813-20, 1997	
	EJ	Hawley-Nelson et al., <i>Focus</i> 15:73-79, 1993	
	EK	He et al., <i>Virology</i> 237:249-60, 1997	
	EL	Heikkinen et al., <i>N. Engl. J. Med.</i> 340:260-4, 1999	
	EM	Hoffman & Banerjee, <i>J. Virol.</i> 71:4272-4277, 1997	
	EN	Holt et al., <i>J. Infect. Dis.</i> 168:1087-96, 1993	
	EO	Hummel & Bellini, <i>J. Virol.</i> 69:1913-6, 1995	
	EP	Jin et al. <i>Virology</i> 251:206-214, 1998	
	EQ	Johnson et al., <i>J. Virol.</i> 71:5060-8, 1997	
	ER	Juhasz et al., <i>J. Virol.</i> 71:5814-5819, 1997	
	ES	Kahn et al., <i>Virology</i> 254:81-91, 1999	
	ET	Karron et al., <i>J. Inf. Dis.</i> 172:1445-1450, 1995	
	EU	Karron et al., <i>Pediatr. Infect. Dis. J.</i> 14:10-16, 1995	
	EV	Karron et al., <i>Pediatr. Infect. Dis. J.</i> 15:650-654, 1996	
	EW	Kato et al., <i>EMBO</i> 16:578-587, 1997	
	EX	Kato et al., <i>Genes to Cells</i> 1:569-579, 1996	
	EY	Kok, <i>Trans. R. Soc. Trop. Med. Hyg.</i> 77:171-6, 1983	
	EZ	Kretschmer et al., <i>Virology</i> 216:309-316, 1996	
	FA	Kretschmar et al., <i>J. Virol.</i> 71:5982-9, 1997	
	FB	Kunkel et al., <i>Methods Enzymol.</i> 154:367-382, 1987	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/733,692	
			Filing Date	December 8, 2000	
			First Named Inventor	Brian R. Murphy	
			Art Unit	1618	
			Examiner Name	Stacy Brown Chen	
Sheet	4	of	6	Attorney Docket Number	1173-1050PUS1

	FC	Lawson et al., <i>Proc. Natl. Acad. Sci. USA</i> 92:4477-81, 1995	
	FD	Markowitz et al., <i>N. Engl. J. Med.</i> 322:580-7, 1990	
	FE	Marx et al., <i>J. Infect. Dis.</i> 176:1423-1427, 1997	
	FF	Mayr et al., <i>Infection</i> 3:6-14, 1975	
	FG	Mayr et al., <i>Zentralbl. Bakteriologie [B]</i> 167:375-90, 1978	ABS
	FH	Mbighuino & Menezes, <i>J. Virol. Methods</i> 31:161-170, 1991	
	FI	Mebatsion et al., <i>J. Virol.</i> 69:1444-1451, 1995	
	FJ	Mebatsion et al., <i>Proc. Natl. Acad. Sci. USA</i> 93:7310-4, 1996	
	FK	Men et al., <i>J. Virol.</i> 70:3930-7, 1996	
	FL	Meyer et al., <i>J. Gen. Virol.</i> 72:1031-1038, 1991	
	FM	Moriya et al., <i>FEBS Lett.</i> 425:105-11, 1998	
	FN	Murphy et al., <i>Infect. Immun.</i> 12:62-68, 1975	
	FO	Murphy, <i>Infectious Diseases in Clinical Practice</i> 2:174-181, 1993	
	FP	Murphy et al., <i>J. Clin. Microbiol.</i> 24:894-8, 1986	
	FQ	Murphy et al., <i>J. Virol.</i> 62:3907-10, 1988	
	FR	Murphy et al., <i>Virus Res.</i> 11:1-15, 1988	
	FS	Nader et al., <i>J. Pediatr.</i> 72:22-8, 1968	
	FT	Needleman & Wunsch, <i>J. Mol. Biol.</i> 48:443-453, 1970	
	FU	Neumann et al., <i>EMBO J.</i> 1:841-845, 1982	
	FV	Norrby & Gollman, <i>Infect. Immun.</i> 11:231-9, 1975	
	FW	Norrby et al., <i>J. Infect. Dis.</i> 132:262-9, 1975	
	FX	Olmsted et al., <i>J. Virol.</i> 63:411-420, 1989	
	FY	Osterhaus et al., <i>Vaccine</i> 16:1479-81, 1998	
	FZ	Palese et al., <i>Proc. Natl. Acad. Sci. USA</i> 93:11354-58, 1996	
	GA	Pearson & Lipman, <i>Proc. Natl. Acad. Sci. USA</i> 85:2444-2448, 1988	
	GB	Perez-Schael et al., <i>N. Engl. J. Med.</i> 337:1181-7, 1997	
	GC	Perrotta & Been, <i>Nature</i> 350:434-436, 1991	
	GD	Peeters et al., <i>J. Virol.</i> 73:5001-5009, 1999	
	GE	Pletnev & Men, <i>Proc. Natl. Acad. Sci. USA</i> 95:1746-51, 1998	
	GF	Polack et al., <i>Nat. Med.</i> 5:629-34, 1999	
	GG	Radecke et al., <i>EMBO J.</i> 14:5773-5784, 1995	
	GH	Radecke & Billeter, <i>Virology</i> 217:418-421, 1996	
	GI	Rauh & Schmidt, <i>Am. J. Dis. Child</i> 109:232-239, 1965	
	GJ	Ray & Compans, <i>Virology</i> 148:232-236, 1986	
	GK	Redfield et al., <i>N. Engl. J. Med.</i> 316:673-676, 1987	
	GL	Reed et al., <i>J. Infect. Dis.</i> 175:807-13, 1997	
	GM	Roberts et al., <i>J. Virol.</i> 72:4704-11, 1998	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/733,692
				Filing Date	December 8, 2000
				First Named Inventor	Brian R. Murphy
				Art Unit	1618
				Examiner Name	Stacy Brown Chen
Sheet	5	of	6	Attorney Docket Number	1173-1050PUS1

	GN	Roberts et al., <i>J. Virol.</i> 73:3723-32, 1999	
	GO	Roberts & Rose, <i>Virology</i> 247:1-6, 1998	
	GP	Roden et al., <i>J. Virol.</i> 70:5875-83, 1996	
	GQ	Rydbeck et al., <i>J. Gen. Virol.</i> 67:1531-1542, 1986	
	GR	Rydbeck et al., <i>J. Gen. Virol.</i> 69:931-5, 1988	
	GS	Sabin et al., <i>J. Infect. Dis.</i> 152:1231-7, 1985	
	GT	Sakai et al., <i>FEBS Lett.</i> 456:221-226, 1999	
	GU	Sato et al., <i>J. Gen. Virol.</i> 66:1397-1409, 1985	
	GV	Schmidt et al., <i>J. Virol.</i> 74:8922-9, 2000	ABS
	GW	Schneider et al., <i>Virology</i> 227:314-322, 1997	
	GX	Schnell et al., <i>Cell</i> 90:849-57, 1997	
	GY	Schnell et al., <i>EMBO J.</i> 13:4195-203, 1994	
	GZ	Schnell et al., <i>J. Virol.</i> 70:2318-23, 1996	
	HA	Schnell et al., <i>Proc. Natl. Acad. Sci. USA</i> 93:11359-65, 1996	
	HB	Sheshberadaran et al., <i>Arch. Virol.</i> 83:251-68, 1985	
	HC	Siegrist & Lambert, <i>Dev. Biol. Stand.</i> 95:133-9, 1998	
	HD	Siegrist et al., <i>Vaccine</i> 16:1409-14, 1998	
	HE	Simasathien et al., <i>Vaccine</i> 15:329-34, 1997	
	HF	Singh & Billeter, <i>J. Gen. Virol.</i> 80:101-6, 1999	
	HG	Singh et al., <i>J. Virol.</i> 73:4823-8, 1999	
	HH	Skiadopoulos et al., <i>J. Virol.</i> 73:1374-81, 1999	
	HI	Skiadopoulos et al., <i>J. Virol.</i> 72:1762-1768, 1998	
	HJ	Skiadopoulos et al., <i>Vaccine</i> 18:503-10, 1999	
	HK	Skiadopoulos et al., <i>Virology</i> 272:225-34, 2000	
	HL	Smith & Waterman, <i>Adv. Appl. Math.</i> 2:482-489, 1981	
	HM	Spielhofer et al., <i>J. Virol.</i> 72:2150-9, 1998	
	HN	Stickle et al., <i>Dtsch. Med. Wochenschr.</i> 99:2386-92, 1974	
	HO	Stokes et al., <i>Virus Res.</i> 25:91-103, 1992	
	HP	Sutter & Moss, <i>Proc. Natl. Acad. Sci. USA</i> 89:10847-10851, 1992	
	HQ	Takimoto et al., <i>J. Virol.</i> 72:9747-54, 1998	
	HR	Tanabayashi Compans, <i>J. Virol.</i> 70:6112-6118, 1996	
	HS	Tao et al., <i>J. Virol.</i> 72:2955-2961, 1998	
	HT	Tao et al., <i>Vaccine</i> 17:1100-8, 1999	
	HU	Taylor et al., <i>Am. J. Epidemiol.</i> 127:788-94, 1988	
	HV	Taylor et al., <i>Virology</i> 187:321-8, 1992	
	HW	Tsurudome et al., <i>J. Gen. Virol.</i> 79:279-89, 1998	
	HX	Tsurudome et al., <i>Virology</i> 171:38-48, 1989	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/733,692	
			Filing Date	December 8, 2000	
			First Named Inventor	Brian R. Murphy	
			Art Unit	1618	
			Examiner Name	Stacy Brown Chen	
Sheet	6	of	6	Attorney Docket Number	1173-1050PUS1

	HY	Tsurudome et al., <i>Virology</i> 213:190-203, 1995	
	HZ	van Wyke Coelingh & Tierney, <i>J. Virol.</i> 63:375-382, 1989	
	IA	van Wyke Coelingh et al., <i>J. Infect. Dis.</i> 157:655-662, 1988	
	IB	van Wyke Coelingh et al., <i>J. Virol.</i> 61:1473-1477, 1987	
	IC	van Wyke Coelingh et al., <i>Virology</i> 143:569-582, 1985	
	ID	van Wyke Coelingh et al., <i>Virology</i> 160:465-72, 1987	
	IE	Walsh et al., <i>J. Gen. Virol.</i> 67:505-513, 1986	
	IF	Werner et al., <i>Archives of Virology</i> 64:247-256, 1980	
	IG	Whelan et al., <i>Proc. Natl. Acad. Sci. USA</i> 92:8388-92, 1995	
	IH	Whitehead et al., <i>J. Virol.</i> 73:9773-9780, 1999	
	II	Whitehead et al., <i>J. Virol.</i> 72:4467-4471, 1998	
	IJ	Whitehead et al., <i>J. Virol.</i> 73:3438-3442, 1999	
	IK	Whitehead et al., <i>Virology</i> 247:232-9, 1998	
	IL	Wigler et al., <i>Cell</i> 14:725-731, 1978	
	IM	Wild et al., <i>J. Gen. Virol.</i> 73:359-67, 1992	
	IN	Wild et al., <i>Vaccine</i> 8:441-2, 1990	
	IO	Wyatt et al., <i>Vaccine</i> 14:1451-1458, 1996	
	IP	Wyatt et al., <i>Virology</i> 210: 202-205, 1995	
	IQ	Yao & Compans, <i>J. Virol.</i> 69:7045-53, 1995	
	IR	Yu et al., <i>Genes to Cells</i> 2:457-66, 1997	
	IU	Fenner et al., World Health Organization, Geneva, 1988 COPY NOT ENCLOSED	
	IV	Griffin et al., In " <i>Fields Virology</i> ", B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus, Eds., Vol. 1, pp. 1267-1312. Lippincott-Raven Publishers, Philadelphia, 1996 COPY NOT ENCLOSED	
	IW	<i>Immunology—A Synthesis</i> , 2nd ed., E. S. Golub & D. R. Gren, eds., Sinauer Associates, Sunderland, Mass., 1991 COPY NOT ENCLOSED	
	IX	Melnick et al., In " <i>Fields Virology</i> ", B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus, Eds., Vol. 1, pp. 655-712. 2 vols. Lippincott-Raven Publishers, Philadelphia, 1996 COPY NOT ENCLOSED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--